PerkinElmer : 2022 JPM Healthcare Conference Presentation

J.P. MORGAN

Healthcare Conference

Prahlad Singh

Chief Executive Officer

January 11, 2022

1

SAFE HARBOR

This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlinkand is available on the "Investor Events" section of our investor relations website at ir.perkinelmer.com.

Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

2

WHO WE ARE

OUR MISSION

Diagnostics

INNOVATING

Life Sciences

for a

healthier

Food

WORLD

Applied

Passionate about saving and transforming patients' lives

Focused on accelerating pre-clinical discoveries and enabling customers to deliver safe and effective therapies

Dedicated to ensuring the highest quality product and keeping the consumer safe

Energized by empowering a cleaner

and safer environment

3

PERKINELMER TODAY

Diagnostics

(Dx)

$5.0B

2021e

revenue

Discovery &

Analytical

Solutions

(DAS)

>16,000 Employees Strong

		Portfolio Mix*
			Consumables,
~45%		~25%		Services,
		Software
Americas		Asia
	~30%			~80%
	Europe
			Instruments
				~20%

2021 Performance† : Continued to Deliver Record Results

Non-COVID	COVID	Adj. EPS
Organic Growth	Revenue	Growth

16%	>$1.5B	30%+
Vs. 2020		Vs. 2020

* YTD through 3Q'21; † Reconciliations of these non-GAAP items to GAAP are provided on our website and here (link)

4

WHAT YOU'LL HEAR TODAY

THE NEW PERKINELMER

Transformation Enabling Faster

Growth and Greater Value Creation

1.	ATTRACTIVE &	Providing complete
EXPANDED PORTFOLIO	solutions across Dx and LS

2.	FOCUSED INTERNAL	Clear progress across
EXECUTION	four strategic priorities

3.	STRONG	Delivering results and
FINANCIAL OUTLOOK	improved financial profile

5